Diabetes

Employer policies for access to maximum benefits do not always match those for access to obesity therapy.

Sanofi's vice president of Diabetes Integrated Care discusses the recent collaboration with Google.

St. Peter's Hospital in New Brunswick won the right to a hearing, where New Jersey's largest insurer will have to say why the Catholic hospital was not included in a preferred network set up alongside a major population health initiative.

Results released by Sanofi and Regeneron of their PCSK9 inhibitor were based on prior clinical trials.

The estimated cost per quality-adjusted life year for the PCSK9 drugs is $300,000. How should health plans respond?

Studies at the American Heart Association show very different approaches to exercise for type 2 diabetes patients.

The study presented at the American Heart Association Scientific Session adds to the evidence that SGLT2s are beneficial in treating hypertension.

The study by the well-known health system could not even test some children because they were too large for the MRI machine.

Despite a recommendation by the American Diabetes Association, many patients in the California public mental healthcare system who have severe mental illness and are taking antipsychotic medications were not being screened annually.

More details are revealed on the first diabetes drug shown to have a cardioprotective benefit, but Yale's Silvio Inzucchi was cautious about assuming the effect applies to the entire SGLT2 inhibitor class.

Studies that measure the effect of walkable communities in Canada and taking the train in Japan show that added steps to one's routine can have positive effects on heart health.

A study finds that a commonly prescribed therapy reduces activity in patients with heart failure with preserved ejection fraction.

Eating out has consequences beyond your wallet, according to research from Harvard.

An obscure notice on CMS' website outlines a proposed revised formula that would take effect in 2017.

From CMS to private health plans, professional healthcare organizations to patients and advocacy groups, the discussion nowadays seems to end up with value.

ADA's theme for American Diabetes Month encourages healthier eating to promote better disease management and prevention.

A list that seeks both the causes and effects of obesity.

What we're reading, November 5, 2015: defensive medicine actually does reduce malpractice risk; patients would like more options for using digital technology with their healthcare; and Americans are eating healthier.

The deal is part of Sanofi's effort to recover ground in the diabetes market.

Approximately half of patients prescribed statins for lowering cholesterol discontinue use within the first year and the adherence rate only goes down from there.

Fifty organizations, including the American Society of Clinical Oncology, have expressed their confidence in Robert Califf, MD, to lead the FDA.

The study found that drugs to treat high cholesterol and diabetes were among those experiencing increased use between 1999-2000 and 2011-2012.

The new meta-analysis was sponsored by the American Diabetes Association and the National Institutes of Health.

Advocacy groups say it's long past time for Medicare to cover continuous glucose monitoring, which is standard of care and funded by most commercial payers.

The study found subtypes aligned by likelihood to be obese, to have cancer or heart disease, or to have mental illness.